

# ASX release

5 September 2024

## Change of Director's Interest – David Koczkar

In accordance with the Listing Rules, Medibank attaches an Appendix 3Y – Change of Director's Interest Notice for David Koczkar for release to the market.

This document has been authorised for release by Mei Ramsay, Company Secretary.

### For further information please contact:

#### For media

Emily Ritchie  
Hub Lead, External Affairs  
M: +61 429 642 418  
Email: [Emily.Ritchie@medibank.com.au](mailto:Emily.Ritchie@medibank.com.au)

#### For investors/analysts

Colette Campbell  
Hub Lead, Investor Relations  
M: +61 475 975 770  
Email: [investor.relations@medibank.com.au](mailto:investor.relations@medibank.com.au)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|   |
|---|
| <b>Name of entity:</b> MEDIBANK PRIVATE LIMITED |
| <b>ABN:</b> 47 080 890 259                      |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                  |
|----------------------------|------------------|
| <b>Name of Director</b>    | David Koczkar    |
| <b>Date of last notice</b> | 18 December 2023 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct (Performance Rights pursuant to the Medibank Private Limited Performance Rights Plan ('Performance Rights Plan'))   |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> |  |
| <b>Date of change</b>   | 2 September 2024   |
| <b>No. of securities held prior to change</b>   | 2,100,777 Performance Rights, being: <ul style="list-style-type: none"><li>• 718,849 Performance Rights granted under the FY22 Long Term Incentive (LTI);</li><li>• 728,840 Performance Rights granted under the FY23 LTI; and</li><li>• 653,088 Performance Rights granted under the FY24 LTI</li></ul> |
| <b>Class</b>  | Performance Rights   |
| <b>Number acquired</b>  | Nil  |

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

|   |   |
|---|---|
| <b>Number disposed</b>  | 718,849 Performance Rights, being 457,907 vested Performance Rights converted to ordinary shares in Medibank Private Limited ( <i>Ordinary Shares</i> ) as set out below and 260,942 lapsed Performance Rights        |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | Performance Rights are granted at nil consideration under the terms of the Performance Rights Plan.   |
| <b>No. of securities held after change</b>  | 1,381,928 Performance Rights, being: <ul style="list-style-type: none"> <li>• 728,840 Performance Rights granted under the FY23 LTI; and</li> <li>• 653,088 Performance Rights granted under the FY24 LTI.</li> </ul> |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Vesting and lapsing of Performance Rights under the Performance Rights Plan   |

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct and Indirect  |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest.                        | Indirect interest in Ordinary Shares held via Olive Man Investments Pty Ltd  |
| <b>Date of change</b>   | 2 September 2024   |
| <b>No. of securities held prior to change</b>   | 1,426,764 Ordinary Shares (indirect)   |
| <b>Class</b>  | Ordinary Shares  |
| <b>Number acquired</b>  | 457,907 Ordinary Shares  |
| <b>Number disposed</b>  | Nil  |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | Acquisition of Ordinary Shares pursuant to vesting and exercise of Performance Rights under the Performance Rights Plan for no consideration.                                |
| <b>No. of securities held after change</b>  | 1,884,671 Ordinary Shares, being: <ul style="list-style-type: none"> <li>• 457,907 Ordinary Shares (direct); and</li> <li>• 1,426,764 Ordinary Shares (indirect).</li> </ul> |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Acquisition of Ordinary Shares pursuant to vesting and exercise of Performance Rights under the Performance Rights Plan.   |

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

|   |     |
|---|-----|
| <b>Detail of contract</b>   | N/A |
| <b>Nature of interest</b>   | N/A |
| <b>Name of registered holder<br/>(if issued securities)</b>   | N/A |
| <b>Date of change</b>   | N/A |
| <b>No. and class of securities to which interest<br/>related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the<br/>interest has changed</small> | N/A |
| <b>Interest acquired</b>  | N/A |
| <b>Interest disposed</b>  | N/A |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated<br/>valuation</small>   | N/A |
| <b>Interest after change</b>  | N/A |

#### Part 3 – <sup>+</sup>Closed period

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts<br/>detailed above traded during a <sup>+</sup>closed period<br/>where prior written clearance was required?</b> | No  |
| <b>If so, was prior written clearance provided to<br/>allow the trade to proceed during this period?</b>  | N/A |
| <b>If prior written clearance was provided, on what<br/>date was this provided?</b>   | N/A |

---

<sup>+</sup> See chapter 19 for defined terms.